SwePub
Sök i LIBRIS databas

  Utökad sökning

onr:"swepub:oai:lup.lub.lu.se:1322eb9d-be3b-4bda-bf1b-d538eb9ebf94"
 

Sökning: onr:"swepub:oai:lup.lub.lu.se:1322eb9d-be3b-4bda-bf1b-d538eb9ebf94" > Pharmacogenomic Ass...

  • McDonough, Caitrin W. (författare)

Pharmacogenomic Association of Nonsynonymous SNPs in SIGLEC12, A1BG, and the Selectin Region and Cardiovascular Outcomes

  • Artikel/kapitelEngelska2013

Nummerbeteckningar

  • LIBRIS-ID:oai:lup.lub.lu.se:1322eb9d-be3b-4bda-bf1b-d538eb9ebf94
  • 000320302600013isi
  • 84880750541scopus
  • 10.1161/HYPERTENSIONAHA.111.00823doi

Ingår i deldatabas

Klassifikation

  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype
  • Ämneskategori:ref swepub-contenttype

Anmärkningar

  • Published
  • 10
  • We sought to identify novel pharmacogenetic markers associated with cardiovascular outcomes in patients with hypertension on antihypertensive therapy. We genotyped a 1:4 case:control cohort (n=1345) on the Illumina HumanCVD Beadchip from the INternational VErapamil SR-Trandolapril STudy (INVEST), where participants were randomized to a -blocker strategy or a calcium channel blocker strategy. Genome-spanning single nucleotide polymorphism (SNP)xtreatment interaction analyses of nonsynonymous SNPs were conducted in white and Hispanic race/ethnic groups. Top hits from whites were tested in Hispanics for consistency. A genetic risk score was constructed from the top 3 signals and tested in the Nordic Diltiazem study. SIGLEC12 rs16982743 and A1BG rs893184 had a significant interaction with treatment strategy for adverse cardiovascular outcomes (INVEST whites and Hispanics combined interaction P=0.0038 and 0.0036, respectively). A genetic risk score, including rs16982743, rs893184, and rs4525 in F5, was significantly associated with treatment-related adverse cardiovascular outcomes in whites and Hispanics from the INVEST study and in the Nordic Diltiazem study (meta-analysis interaction P=2.39x10(-5)). In patients with a genetic risk score of 0 or 1, calcium channel blocker treatment was associated with lower risk (odds ratio [95% confidence interval]=0.60 [0.42-0.86]), and in those with a genetic risk score of 2 to 3, calcium channel blocker treatment was associated with higher risk (odds ratio [95% confidence interval]=1.31 [1.08-1.59]). These results suggest that cardiovascular outcomes may differ based on SIGLEC12, A1BG, F5 genotypes, and antihypertensive treatment strategy. These specific genetic associations and our risk score provide insight into a potential approach to personalized antihypertensive treatment selection.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Gong, Yan(SwePub:) (författare)
  • Padmanabhan, Sandosh(SwePub:) (författare)
  • Burkley, Ben(SwePub:) (författare)
  • Langaee, Taimour Y.(SwePub:) (författare)
  • Melander, Olle,Forskargrupper vid Lunds universitet, Lund University Research Groups, Lunds universitet, Lund University, Kardiovaskulär forskning - hypertoni, Cardiovascular Research - Hypertension(SwePub:) (författare)
  • Pepine, Carl J.(SwePub:) (författare)
  • Dominiczak, Anna F.(SwePub:) (författare)
  • Cooper-DeHoff, Rhonda M.(SwePub:) (författare)
  • Johnson, Julie A.(SwePub:) (författare)

Sammanhörande titlar

  • Ingår i:HypertensionLippincott Williams & Wilkins1524-456362:1, s. 48-54

Internetlänk

Hitta via bibliotek

Till lärosätets databas

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy